Corporate Finance & Consulting  
 
 
Home Page > Replicon Group
 



Xtract raises € 2 million in venture capital funding from Eqvitec
08-03-2007,

From Press release
March 8, 2007

Xtract, the customer analytics expert, today announced that € 2 million in growth capital funding has been secured in a first round of funding from one of the largest technology focused funds in Northern Europe, Eqvitec Technology Fund III. A second round of growth funding is expected to be raised later in 2007.

Xtract is specialised in automated customer analytics solutions, enabling the analysis and prediction of events supporting targeted advertising in online communities and social networks. The funding will be used to further expand internationally, growing the customer base for the Xtract proprietary solutions, which include mobile advertising solutions to advertisers, as well as community and social networking analytics.


Reference:
Replicon News on Disclosed Servicing Package in December 2006

About Xtract
Xtract (www.xtract.info) helps deliver efficient mobile and community marketing by making complexity simple and actionable – giving meaning and life to raw customer data. Xtract is a customer analytics expert, predicting customer behaviour, with core strengths in mobile, social network and analytical optimization. Xtract enables marketing departments to leverage and deliver on the potential of their brand assets, by understanding who their customers are and how they behave, what communities they belong to and how they interact within those communities. Xtract is based in Helsinki, and operates across Europe and Asia, working with blue-chip companies in a variety of sectors such as mobile, finance, retail, media, and internet, including leading mobile operators, service providers, and handset manufacturer.

About EQVITEC Partners Oy
EQVITEC Partners Oy, is one of the largest technology focused venture capital firms in Northern Europe. The company was founded in 1997 and employs 16 investments professionals in Helsinki and Stockholm. EQVITEC Partners currently advises five funds with a total capital base of 440 million euros. The funds invest mainly in early and growth phase technology companies. At the moment the funds have investments in 40 technology companies and have successfully carried out 26 exits. More information can be found at www.eqvitec.com


About Replicon
Replicon Group is an independent corporate finance, consulting and asset management advisory house based in Helsinki. Replicon provides strategic and financial solutions that facilitate business activities, efficiency, and increase profitability of corporations and other organizations. Our core competence is in the corporate solutions that facilitate and govern growth of businesses based on innovation. An important part of our activities is continuous learning. We want to find and develop most suitable solutions to our customer needs. Replicon Group’s special focus areas are Life-Science and ICT/Mobile sectors. In these sectors Replicon provides also asset management advisory. The main shareholders in Replicon Group are its key management, holding majority of the company’s shares. Replicon’s homepage is www.replicon.fi


Recent articles:

> 19-08-2010 - Valuation Services and Total Life Cycle Cost Analyses

> 04-05-2010 - Oversol Oy / Lumi Group Oy Raises First Part of 2-4 M€ Financing

> 22-03-2010 - Replicon Continues as Certified Adviser in NASDAQ OMX First North

> 22-03-2010 - Replicon Group jatkaa NASDAQ OMX:ssä neuvonantajana

> 22-01-2010 - Replicon Initiates Multimillion Financing Project for Promising LED Application

> 06-10-2009 - Replicon Newsletter Q3/2009

> 09-09-2009 - New Certification for Replicon Group

> 24-08-2009 - Replicon toimittaa asiantuntija-palvelupaketin Qentinel Oy:lle

> 17-08-2009 - ASIAVIIHDE: videoidut talouskirja-arvostelut

> 16-06-2009 - Replicon Group Company Awarded 2 Year R&D Project

> 21-05-2009 - Replicon Newsletter Q2/2009

> 21-05-2009 - Repliconin Uutiskirje Q2/2009

> 03-02-2009 - Replicon Newsletter Q1/2009

> 19-01-2009 - Jouko Ahvenainen Presenting in Mobile World Congress in Barcelona

> 19-12-2008 - Replicon Creates an Option Arrangement for Its Client

> 29-10-2008 - Results from Client Survey

> 18-09-2008 - Tuottavuus ja rahoitus 2008 -seminaari

> 17-06-2008 - Ani Biotech buys the Business Operations of Orgenium Laboratories

> 20-05-2008 - Tietoisku FIRST NORTH -markkinapaikasta

> 31-03-2008 - Replicon Collaboration Partner Forms Global Multi-Centre Network

> 30-01-2008 - Replicon helps EVE to Receive Private Equity Financing

> 29-01-2008 - Replicon Pharma Portfolio Outperforms Benchmark Index Fifth Year in a Row

> 29-11-2007 - Replicon Group OMX First Northin Certified Adviseriksi

> 29-11-2007 - Replicon Group becomes Certified Adviser in OMX First North

> 28-11-2007 - Matti Copeland Repliconin neuvonantajaksi

> 15-10-2007 - Replicon Private Equity -tapahtuma

> 24-09-2007 - Talentor Receives Private Equity Financing Package in Record Time

> 07-08-2007 - Meet Replicon in Autumn 2007

> 11-05-2007 - Replicon and Imanext Form Strategic Collaboration

> 17-04-2007 - Pääjohtaja Liikanen puhumassa Repliconin Tuottavuus -seminaarissa

> 17-04-2007 - BoF Governor Speaking at Replicon Productivity Seminar

> 09-03-2007 - Top Seminar: ICT Companies as Productivity Boosters

> 08-03-2007 - Xtract raises € 2 million in venture capital funding from Eqvitec

> 21-02-2007 - ICT-yritykset tuottavuuden nostajina - Repliconin Tuottavuus ja rahoitus -seminaari 17.4.2007

> 29-01-2007 - Replicon MDF Portfolio Outperforms Benchmark Index Fourth Year in a Row

> 29-01-2007 - Repliconin Pharma portfolio (MDF) ylittänyt jälleen vertailuindeksin tuoton

> 08-01-2007 - Replicon toimittaa asiantuntijapalvelupaketin Qentinel Oy:lle

> 15-12-2006 - Replicon Provides Expert Services for Xtract, Ltd.

> 01-11-2006 - Replicon Provides Compensation Arrangement Planning for Growth Companies

> 01-11-2006 - Replicon toteuttaa osakesidonnaisia kannustinjärjestelmiä kasvuyrityksille

> 26-10-2006 - Petteri Hirvonen Presenting in Global UMTS TDD Alliance Summit in London

> 28-09-2006 - Jouko Ahvenainen Presenting in Mobile Marketing Service Summit in Lisbon

> 29-05-2006 - First Half Management Consulting Projects of Replicon

> 01-04-2006 - Replicon Launches Investigational Asset Management Portfolio in ICT sector

> 02-03-2006 - Enfucell Receives First VC Round of Financing

> 20-02-2006 - Replicon Helps Arranging Significant Financing Package for a Client

> 29-01-2006 - Replicon Portfolio Outperforms Benchmark Third Year in a Row

> 02-01-2006 - Replicon Hires Satu Vapaakallio as Analyst

> 24-11-2005 - Replicon Initiate 7.5Meur Private Placement Process for SkyWeb Oy

> 14-10-2005 - CTT Cancer Targeting Technologies Ltd enters into R&D agreement with GE Healthcare

> 05-09-2005 - Orgenium receives financing from Abroad and Expands Production to Low Cost Production Site in Ankara, Turkey

> 20-07-2005 - Replicon helps arranging financing for #CMAX.gg

> 31-03-2005 - Replicon in BioFinland 05 Investor Forum

> 29-01-2005 - Replicon Biotech Value Portfolio Outperforms NASDAQ Biotech Index Second Year in a Row

> 26-01-2005 - Replicon Extends Its Life Science Expert Team

> 18-01-2005 - All Replicon Senior Partners Gain Accreditation by the Ministry of Trade and Industry

> 10-01-2005 - Jouko Ahvenainen (MBA, M.Sc.) joins Replicon as a Senior Partner

> 17-12-2004 - Replicon to Develop a Model for Enhancing Commercialization of Bone Research in Finland

> 29-10-2004 - Replicon moves to WTC Helsinki

> 15-10-2004 - MBA Petri Laulajainen joins Replicon as a Senior Partner

> 02-07-2004 - Orgenium closes financing round with private investors and Finnish Industry Investment Ltd.

> 27-05-2004 - Replicon's new strategic partners announced

> 07-04-2004 - Viope closes financing round for expansion

> 29-01-2004 - Replicon Biotech Model Portfolio Annual Return 78 per cent

> 15-12-2003 - Replicon enters into a two-year business development partnership

> 19-08-2003 - Dr. Hannu Silvennoinen joins as a Senior Partner

> 09-04-2003 - Replicon forms corporate finance unit

> 28-01-2003 - Replicon Launches Model Portfolio in Biotech

 
© 2003, Replicon